Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
about
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stressClinical Management of Priapism: A ReviewClinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateA pathophysiology-based approach to the management of early priapismMedical management of ischemic stuttering priapism: a contemporary review of the literatureMolecular pathophysiology of priapism: emerging targetsEstablishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.Post-translational inactivation of endothelial nitric oxide synthase in the transgenic sickle cell mouse penisAdenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapismHow I manage priapism in chronic myeloid leukaemia patients.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Management of priapism: an update for clinicians.Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsPriapism in sickle-cell disease: a hematologist's perspective.Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penisPDE5 inhibitors beyond erectile dysfunction.Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell miceNovel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapyEvaluation and management of priapism: 2009 updateInvestigational noncardiovascular uses of phosphodiesterase-5 inhibitors.Treating stuttering priapism.Nitrergic Mechanisms for Management of Recurrent PriapismDevelopment and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction.How I treat priapism.Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.Advances in the understanding of priapism.Anxiety related to sexual abuse: A case of recurrent priapismErectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors.Contemporary best practice in the evaluation and management of stuttering priapism.The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathwayPhosphodiesterase type 5 and cancers: progress and challenges.Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.Recent advances in the management of priapism.Clinical course linkage among different priapism subtypes: Dilemma in the management strategies.Idiopathic stuttering priapism treated with salbutamol orally: a case report.Daily tadalafil for the chronic phase of stuttering priapism: a case report.
P2860
Q21559608-28BC2C1B-7D86-45B4-BE0C-F713D1F18584Q26750575-16882110-E3E6-4C70-A584-7C8A06F7CCD4Q26775925-DF4F849C-5009-4D6F-846E-F7EFBBFDB5AEQ26825268-F7455A79-66C7-4A51-B9E8-3F752D367508Q26851728-127F4FCC-B2E9-4B93-8634-5BF1BC5B7E16Q27010069-1F6683CD-B84B-418A-8687-2F70B807AE28Q33572814-DC099D12-BD62-41F8-9D15-5FCB92408A1BQ33859035-CB178729-4824-4274-A192-7F84474ECA6CQ33873920-A739A067-A15B-4BB1-AC11-0DE0F7268DBCQ34005421-93472DCD-D79A-4527-816F-F68E61D4DEE9Q34031890-BC2AC074-6900-411A-A63F-FE4C0A40409DQ34244951-7A1E4395-77E4-46A1-9235-ABD5D6821ACFQ34536704-5143D8B7-F198-4C31-92B1-12138CF6B0C6Q34898802-13D2F2D8-6F1C-4185-9F1D-F8C40DED9545Q34992760-7B079917-44F7-4228-A313-6184695E7344Q35658625-1E2C066A-F562-4B43-BE29-0F02E8FB6B90Q36213625-8ED076ED-B07A-4F13-9FC6-B4D3B244DEE3Q36878017-0FC58BF0-4581-453E-B72E-EF333A4E091BQ37084173-80445B33-DCA6-458F-9502-448893803859Q37146167-14530CCF-DA0C-4B08-97B4-A3A22169BBCEQ37346719-135C20E5-6D77-4FF8-965C-31E8038A9236Q37415993-E6F3298F-F916-4522-8DAC-B621EF93A158Q37474332-7F2D8DCE-E4E8-4EBF-8F78-A00DF6FE28CEQ37903037-915C5260-4FEE-4C4C-B2C1-7947C86A12A9Q37931389-98CCF0DF-3C71-4886-AD6E-6EFEFB964C2CQ38610620-ACB33226-E660-417C-BE55-A0925130798CQ38889467-F8F9AB78-42A8-4A07-8F21-C780290F0BFBQ39025090-EB8457A0-26BB-48F0-BEF2-5627A45DCBE7Q39290264-D6DED354-47B2-467E-99EA-6E90D1106282Q39327895-4C91F1AE-B261-45F0-B16A-2D8BB2DF6239Q40612806-42269EB0-DDB7-4680-AF42-19E3466AEF11Q40852821-516A1796-34BE-4493-A7E1-3FC65C8CD9F8Q41078738-495A58BC-2035-4508-B901-73D1DAA33EDAQ42603490-BF740274-B75C-42C6-97D6-126E13C40635Q47171803-269FEA76-A21C-418C-BB55-DA2F194A12B5Q47700617-F86F9BE2-91E5-458E-8AB6-848EB9F47BB1Q49309989-6E915B1D-78F0-4F8C-93B4-1BA07F9E988AQ50778371-F7B1441C-214D-49EE-95D0-24006658EA44Q53484383-55A370D0-0B90-4BF1-AAC1-33D2B8A223B0Q55154654-B3F34A9C-6C18-4A81-B1A0-8947A1449515
P2860
Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Feasibility of the use of phos ...... rogram for recurrent priapism.
@ast
Feasibility of the use of phos ...... rogram for recurrent priapism.
@en
Feasibility of the use of phos ...... rogram for recurrent priapism.
@nl
type
label
Feasibility of the use of phos ...... rogram for recurrent priapism.
@ast
Feasibility of the use of phos ...... rogram for recurrent priapism.
@en
Feasibility of the use of phos ...... rogram for recurrent priapism.
@nl
prefLabel
Feasibility of the use of phos ...... rogram for recurrent priapism.
@ast
Feasibility of the use of phos ...... rogram for recurrent priapism.
@en
Feasibility of the use of phos ...... rogram for recurrent priapism.
@nl
P2093
P1476
Feasibility of the use of phos ...... rogram for recurrent priapism.
@en
P2093
Arthur L Burnett
Biljana Musicki
Hunter C Champion
Trinity J Bivalacqua
P304
P356
10.1111/J.1743-6109.2006.00333.X
P577
2006-11-01T00:00:00Z